XML 17 R6.htm IDEA: XBRL DOCUMENT v3.25.3
CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY - USD ($)
$ in Thousands
Common Stock
Additional Paid-in Capital
Accumulated Other Comprehensive Income (Loss)
Accumulated Deficit
Total
Balance at beginning of period at Dec. 31, 2023 $ 1 $ 928,080 $ (106) $ (770,796) $ 157,179
Balance at beginning of period (in shares) at Dec. 31, 2023 70,894,889        
Increase (Decrease) in Stockholders' Equity          
Issuance of common stock in connection with vesting of restricted stock units   (55)     (55)
Issuance of common stock in connection with vesting of restricted stock units (in shares) 353,128        
Unrealized gain (loss) on marketable securities     (258)   (258)
Stock-based compensation expense   2,089     2,089
Net loss       (16,941) (16,941)
Balance at end of period at Mar. 31, 2024 $ 1 930,114 (364) (787,737) 142,014
Balance at end of period (in shares) at Mar. 31, 2024 71,248,017        
Balance at beginning of period at Dec. 31, 2023 $ 1 928,080 (106) (770,796) 157,179
Balance at beginning of period (in shares) at Dec. 31, 2023 70,894,889        
Increase (Decrease) in Stockholders' Equity          
Net loss         (35,513)
Balance at end of period at Sep. 30, 2024 $ 1 936,032 427 (806,309) 130,151
Balance at end of period (in shares) at Sep. 30, 2024 71,417,513        
Balance at beginning of period at Mar. 31, 2024 $ 1 930,114 (364) (787,737) 142,014
Balance at beginning of period (in shares) at Mar. 31, 2024 71,248,017        
Increase (Decrease) in Stockholders' Equity          
Issuance of common stock in connection with vesting of restricted stock units   (10)     (10)
Issuance of common stock in connection with vesting of restricted stock units (in shares) 84,808        
Unrealized gain (loss) on marketable securities     (99)   (99)
Stock-based compensation expense   2,903     2,903
Net loss       (10,986) (10,986)
Balance at end of period at Jun. 30, 2024 $ 1 933,007 (463) (798,723) 133,822
Balance at end of period (in shares) at Jun. 30, 2024 71,332,825        
Increase (Decrease) in Stockholders' Equity          
Issuance of common stock in connection with vesting of restricted stock units   21     21
Issuance of common stock in connection with vesting of restricted stock units (in shares) 84,688        
Unrealized gain (loss) on marketable securities     890   890
Stock-based compensation expense   3,004     3,004
Net loss       (7,586) (7,586)
Balance at end of period at Sep. 30, 2024 $ 1 936,032 427 (806,309) 130,151
Balance at end of period (in shares) at Sep. 30, 2024 71,417,513        
Balance at beginning of period at Dec. 31, 2024 $ 1 1,058,317 97 (902,861) $ 155,554
Balance at beginning of period (in shares) at Dec. 31, 2024 107,850,124       107,850,124
Increase (Decrease) in Stockholders' Equity          
Issuance of common stock in connection with vesting of restricted stock units   (275)     $ (275)
Issuance of common stock in connection with vesting of restricted stock units (in shares) 415,405        
Unrealized gain (loss) on marketable securities     337   337
Stock-based compensation expense   3,535     3,535
Net loss       (15,085) (15,085)
Balance at end of period at Mar. 31, 2025 $ 1 1,061,577 434 (917,946) 144,066
Balance at end of period (in shares) at Mar. 31, 2025 108,265,529        
Balance at beginning of period at Dec. 31, 2024 $ 1 1,058,317 97 (902,861) $ 155,554
Balance at beginning of period (in shares) at Dec. 31, 2024 107,850,124       107,850,124
Increase (Decrease) in Stockholders' Equity          
Net loss         $ (45,128)
Balance at end of period at Sep. 30, 2025 $ 1 1,067,491 597 (947,989) $ 120,100
Balance at end of period (in shares) at Sep. 30, 2025 108,342,592       108,342,592
Balance at beginning of period at Mar. 31, 2025 $ 1 1,061,577 434 (917,946) $ 144,066
Balance at beginning of period (in shares) at Mar. 31, 2025 108,265,529        
Increase (Decrease) in Stockholders' Equity          
Issuance of common stock in connection with vesting of restricted stock units   (9)     (9)
Issuance of common stock in connection with vesting of restricted stock units (in shares) 63,265        
Unrealized gain (loss) on marketable securities     48   48
Stock-based compensation expense   3,063     3,063
Net loss       (15,429) (15,429)
Balance at end of period at Jun. 30, 2025 $ 1 1,064,631 482 (933,375) 131,739
Balance at end of period (in shares) at Jun. 30, 2025 108,328,794        
Increase (Decrease) in Stockholders' Equity          
Issuance of common stock in connection with vesting of restricted stock units (in shares) 13,798        
Unrealized gain (loss) on marketable securities     115   115
Stock-based compensation expense   2,860     2,860
Net loss       (14,614) (14,614)
Balance at end of period at Sep. 30, 2025 $ 1 $ 1,067,491 $ 597 $ (947,989) $ 120,100
Balance at end of period (in shares) at Sep. 30, 2025 108,342,592       108,342,592